PDF下载 分享
[1]吴祖泽,等.新蛭素和人IgG-Fc 融合蛋白的表达纯化和功能评价 [J].天津大学学报(自然科学与工程技术版),2019,52(02):136-142.[doi:10.11784/tdxbz201803084]
 Wu Zuze,Wang Kun,et al.Expression,Purification and Functional Evaluation of Neorudin-Human IgG-Fc Fusion Protein [J].Journal of Tianjin University(Science and Technology),2019,52(02):136-142.[doi:10.11784/tdxbz201803084]
点击复制

新蛭素和人IgG-Fc 融合蛋白的表达纯化和功能评价

参考文献/References:

[1] Markwardt F. Hirudin as alternative anticoagulant—A historical review[J]. Seminars in Thrombosis and Hemostasis,2002,28(5):405-414.
[2] Sohn J,Kang H,Rao K,et al. Current status of the anticoagulant hirudin:Its biotechnological production and clinical practice[J]. Applied Microbiology and
Biotechnology,2001,57(5/6):606-613.
[3] Lubenow N,Greinacher A. Hirudin in heparin-induced thrombocytopenia[J]. Seminars in Thrombosis and Hemostasis,2002,28(5):431-438.
[4] Nisio M D,Middeldorp S,Büller H R. Direct thrombin inhibitors[J]. The New England Journal of Medicine,2005,353(10):1028-1040.
[5] Zhang C,Yu A,Yuan B,et al. Construction and functional evaluation of hirudin derivatives with low bleeding risk[J]. Thromb Haemost,2008,99(2):324-330.
[6] 王文文,徐向伟,赵专友. 谷氨酸-脯氨酸-精氨酸-水蛭素抑制血栓形成的实验研究[J]. 中国药学杂志,2013,48 (2):111-115. Wang Wenwen,Xu Xiangwei Zhao Zhuanyou,et al. Anti-thrombus activity of a novel anti-thrombus protein EPR-hirudin[J]. Chinese Pharmaceutical Journal ,2013,48(2):111-115(in Chinese).
[7] Dong Xiaona,Meng Zhiyun,Jin Jide. Development,validation,and clinical pharmacokinetic application of ultraperformance liquid chromatography/tandem mass spectrometry method for simultaneously determining a novel recombinant hirudin derivative(neorudin)and its active metabolite in human serum[J]. Journal of
Chromatography B,2017,1063:204-213.
[8] Jonathan T S,Szoka F C. The neonatal Fc receptor,FcRn,as a target for drug delivery and therapy[J]. Adv Drug Deliv Rev,2015,91(30):109-124.
[9] Chen X Y,Zaro J L,Shen W C. Fusion protein linkers:Property,design and functionality[J]. Adv Drug Deliv Rev,2013,65(10):1357-1369.
[10] Czajkowsky D M,Hu J,Shao Z,et al. Fc-fusion proteins:New developments and future perspectives[J]. EMBO Mol Med,2012,4(10):1015-1028.
[11] 秦晓永,于爱平,毕建进. 抗凝蛋白EH 体外活性检测条件的建立[J]. 中国生物工程杂志,2010,31(5):108-112. Qin Xiaoyong,Yu Aiping,Bi Jianjin. The anticoagulant activity detection of EH in vitro[J]. China Biotechnology,2010,31(5):108-112(in Chinese).
[12] Van Witteloostuijn S B,Pedersen S L,Jensen K J. Half-life extension of biopharmaceuticals using chemical methods :Alternatives to PEGylation[J]. ChemMed-Chem,2016,11(22):2474-2495.
[13] Jevsevar S,Kunstelj M,Porekar V G. PEGylation of therapeutic proteins[J]. Biotechnol J,2010, 5(1):113-128.
[14] Caliceti P , Veronese F M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates[J]. Advanced Drug Delivery Reviews,2003,55(10):1261-1277.
[15] Strohl W R. Fusion proteins for half-life extension of biologics as a strategy to make biobetters[J]. Biodrugs,2015,29(4):215-239.
[16] Rath T,Baker K,Dumont J A,et al. Fc-fusion proteins and FcRn:Structural insights for longer-lasting and more effective therapeutics[J]. Crit Rev Biotechnol,2015,35(2):235-254.
[17] Roopenian D C,Akilesh S. FcRn:The neonatal Fc receptor comes of age[J]. Nat Rev Immunol,2007,7(9):715-725.
[18] Kontermann R E. Strategies for extended serum half-life of protein therapeutics[J]. Curr Opin Biotechnol,2011,22(6):868-876.
[19] Kontermann R E. Strategies to extend plasma half-lives of recombinant antibodies[J]. Biodrugs,2009,23(2):93-109.
[20] Strohl W R. Current progress in innovative engineered antibodies[J]. Protein Cell,2017,9(1):86-120.
[21] Zhao H L,Yao X Q,Xue C,et al. Increasing the homogeneity,stability and activity of human serum albumin and interferon-α2b fusion protein by linker
engineering[J]. Protein Expression and Purification,2008,61(1):73-77.

备注/Memo

通信作者:靳继德,jinjide505@163.com.

更新日期/Last Update: 2019-01-22